SCHEMBL328458

SCHEMBL328458

O=C(O)c1ccccc1C(=O)Nc1ccccc1SCCS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 1.00
KMT2A Q03164 6/20 0.55
MEN1 O00255 5/20 0.55
ALDH1A1 P00352 4/20 0.52
LMNA P02545 2/20 0.52
HPGD P15428 1/20 0.52
IRS1 P35568 1/20 0.49
GAB1 Q13480 1/20 0.49
SLC16A1 P53985 1/20 0.44
CCR2 P41597 2/20 0.42
CCR1 P32246 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
GAA P10253 1/20 0.41
ALOX12 P18054 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11891825 0.92 AKT1 (0.85) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL328426 0.90 AKT1 (0.82) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11891838 0.88 AKT1 (0.79) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11891821 0.88 AKT1 (0.78) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11891819 0.88 AKT1 (0.78) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11893045 0.87 AKT1 (0.77) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11891816 0.87 AKT1 (0.77) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11891812 0.87 AKT1 (0.77) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11891813 0.87 AKT1 (0.77) AKT1KMT2AMEN1ALDH1A1LMNA
SCHEMBL11891831 0.87 AKT1 (0.77) AKT1KMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648255-B2 Inhibitors for treatment of hematological malignancies MASARYKOVA UNIVERZITA (CZ) 2023-05-16 US disclosed
US-20220000879-A1 Inhibitors for Treatment of Hematological Malignancies MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20200396995-A1 INHIBITORS OF GRB2-ASSOCIATED BINDING PROTEIN 1 (GAB1) AND METHODS OF TREATING CANCER USING THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2020-12-24 US disclosed
US-10448637-B2 Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2019-10-22 US disclosed
US-20170311597-A1 INHIBITORS OF GRB2-ASSOCIATED BINDING PROTEIN 1 (GAB1) AND METHODS OF TREATING CANCER USING THE SAME ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA (US) 2017-11-02 US disclosed
EP-2428504-B1 Small molecule inhibitors of the pleckstrin homology domain and method for using same UNIV TEXAS (US) 2017-05-17 EP disclosed
US-9320734-B2 Small molecule inhibitors of the pleckstrin homology domain and methods for using same BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-04-26 US disclosed
US-20150126563-A1 SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-05-07 US disclosed
US-8962663-B2 Small molecule inhibitors of the pleckstrin homology domain and methods for using same BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-02-24 US disclosed
US-20130184317-A1 SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2013-07-18 US disclosed
US-8420678-B2 Small molecule inhibitors of the pleckstrin homology domain and methods for using same BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-04-16 US disclosed
US-20120189670-A1 PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME PHUSIS THERAPEUTICS INC. 2012-07-26 US disclosed
EP-2428504-A1 Small molecule inhibitors of the pleckstrin homology domain and method for using same The Board of Regents of the University of Texas System (US) 2012-03-14 EP disclosed
US-20110144066-A1 SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-06-16 US disclosed
WO-2011032169-A2 PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME PHUSIS THERAPEUTICS INC. (US) 2011-03-17 WO disclosed
WO-2009129267-A2 SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144066-A1 SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME PLEKHG3, PLEKHA1, PLEC AKT1 92/4885KMT2A 3162/4885MEN1 1607/4885
US-20150126563-A1 SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME PLEKHG3, PLEKHA1, PLEC AKT1 92/4885KMT2A 3162/4885MEN1 1607/4885
US-20200396995-A1 INHIBITORS OF GRB2-ASSOCIATED BINDING PROTEIN 1 (GAB1) AND METHODS OF TREATING CANCER USING THE SAME GAB1, GRB2, BCR AKT1 878/4885KMT2A 1958/4885MEN1 2912/4885
US-20170311597-A1 INHIBITORS OF GRB2-ASSOCIATED BINDING PROTEIN 1 (GAB1) AND METHODS OF TREATING CANCER USING THE SAME GAB1, GRB2, BCR AKT1 1479/4885KMT2A 2240/4885MEN1 3346/4885
US-20130184317-A1 SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME PLEKHG3, PLEKHA1, PLEC AKT1 92/4885KMT2A 3162/4885MEN1 1607/4885
US-20220000879-A1 Inhibitors for Treatment of Hematological Malignancies GAB1, BTK, MCL1 AKT1 1250/4885KMT2A 457/4885MEN1 1850/4885
US-10448637-B2 Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same GAB1, GRB2, BCR AKT1 1479/4885KMT2A 2240/4885MEN1 3346/4885
US-20120189670-A1 PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME PLEKHG3, PLEC, PLEKHA1 AKT1 80/4885KMT2A 4375/4885MEN1 955/4885
US-11648255-B2 Inhibitors for treatment of hematological malignancies GAB1, BTK, MCL1 AKT1 1250/4885KMT2A 457/4885MEN1 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.